189 related articles for article (PubMed ID: 34846515)
1. Report From the National Eye Institute Workshop on Neuro-Ophthalmic Disease Clinical Trial Endpoints: Optic Neuropathies.
Levin LA; Sengupta M; Balcer LJ; Kupersmith MJ; Miller NR
Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):30. PubMed ID: 34846515
[No Abstract] [Full Text] [Related]
2. Use of patient-reported outcomes in medical product development: a report from the 2009 NEI/FDA Clinical Trial Endpoints Symposium.
Varma R; Richman EA; Ferris FL; Bressler NM
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6095-103. PubMed ID: 21123768
[No Abstract] [Full Text] [Related]
3. FDA ovarian cancer clinical trial endpoints workshop: A Society of Gynecologic Oncology White Paper.
Herzog TJ; Ison G; Alvarez RD; Balasubramaniam S; Armstrong DK; Beaver JA; Ellis A; Tang S; Ford P; McKee A; Gershenson DM; Kim G; Monk BJ; Pazdur R; Coleman RL
Gynecol Oncol; 2017 Oct; 147(1):3-10. PubMed ID: 28844539
[No Abstract] [Full Text] [Related]
4. Report From the NEI/FDA Diabetic Retinopathy Clinical Trial Design and Endpoints Workshop.
Nair P; Aiello LP; Gardner TW; Jampol LM; Ferris FL
Invest Ophthalmol Vis Sci; 2016 Oct; 57(13):5127-5142. PubMed ID: 27699406
[No Abstract] [Full Text] [Related]
5. Ophthalmic Drug Discovery and Development: Regulatory Aspects of Patient Focused Drug Development in Ophthalmology.
Rowe-Rendleman CL
Pharm Res; 2019 Feb; 36(4):54. PubMed ID: 30790065
[TBL] [Abstract][Full Text] [Related]
6. Glaucoma research community and FDA look to the future, II: NEI/FDA Glaucoma Clinical Trial Design and Endpoints Symposium: measures of structural change and visual function.
Weinreb RN; Kaufman PL
Invest Ophthalmol Vis Sci; 2011 Oct; 52(11):7842-51. PubMed ID: 21972262
[No Abstract] [Full Text] [Related]
7. The Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC).
Kupersmith MJ; Miller N; Balcer L; Gordon L; Wall M; Keltner J; Friedman D; Feldon S; McDermott M; Kieburtz K
J Neuroophthalmol; 2009 Sep; 29(3):259-61. PubMed ID: 19726952
[No Abstract] [Full Text] [Related]
8. Special Commentary: Early Clinical Development of Cell Replacement Therapy: Considerations for the National Eye Institute Audacious Goals Initiative.
Levin LA; Miller JW; Zack DJ; Friedlander M; Smith LEH
Ophthalmology; 2017 Jul; 124(7):926-934. PubMed ID: 28365209
[TBL] [Abstract][Full Text] [Related]
9. Neuro-Ophthalmology at a Tertiary Eye Care Centre in India.
Dhiman R; Singh D; Gantayala SP; Ganesan VL; Sharma P; Saxena R
J Neuroophthalmol; 2018 Sep; 38(3):308-311. PubMed ID: 29135814
[TBL] [Abstract][Full Text] [Related]
10. Report from the NEI/FDA Ophthalmic Clinical Trial Design and Endpoints Symposium.
Csaky KG; Richman EA; Ferris FL
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):479-89. PubMed ID: 18234989
[No Abstract] [Full Text] [Related]
11. The 2021 National Eye Institute Strategic Plan: Eliminating Vision Loss and Improving Quality of Life.
Chiang MF; Tumminia SJ
Ophthalmology; 2022 Jan; 129(1):12-14. PubMed ID: 34736763
[No Abstract] [Full Text] [Related]
12. Report on the National Eye Institute Audacious Goals Initiative: Regenerating the Optic Nerve.
Goldberg JL; Guido W;
Invest Ophthalmol Vis Sci; 2016 Mar; 57(3):1271-5. PubMed ID: 26990163
[TBL] [Abstract][Full Text] [Related]
13. Ophthalmic Clinical Trials: We've Come a Long Way, Baby.
Sommer A
Am J Ophthalmol; 2020 Jan; 209():1-2. PubMed ID: 31420095
[No Abstract] [Full Text] [Related]
14. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium.
Leon MB; Piazza N; Nikolsky E; Blackstone EH; Cutlip DE; Kappetein AP; Krucoff MW; Mack M; Mehran R; Miller C; Morel MA; Petersen J; Popma JJ; Takkenberg JJ; Vahanian A; van Es GA; Vranckx P; Webb JG; Windecker S; Serruys PW
J Am Coll Cardiol; 2011 Jan; 57(3):253-69. PubMed ID: 21216553
[TBL] [Abstract][Full Text] [Related]
15. Some remaining challenges regarding multiple endpoints in clinical trials.
Snapinn S
Stat Med; 2017 Dec; 36(28):4441-4445. PubMed ID: 28664566
[TBL] [Abstract][Full Text] [Related]
16. The glaucoma research community and FDA look to the future: a report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium.
Weinreb RN; Kaufman PL
Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1497-505. PubMed ID: 19321793
[No Abstract] [Full Text] [Related]
17. Endpoints in respiratory diseases.
de Benedictis FM; Guidi R; Carraro S; Baraldi E;
Eur J Clin Pharmacol; 2011 May; 67 Suppl 1():49-59. PubMed ID: 21104409
[TBL] [Abstract][Full Text] [Related]
18. Patients With Migraine Have Substantial Reductions in Measures of Visual Quality of Life.
Hanson LL; Ahmed Z; Katz BJ; Warner JEA; Crum AV; Zhang Y; Zhang Y; Baggaley S; Pippitt K; Cortez MM; Digre KB
Headache; 2018 Jul; 58(7):1007-1013. PubMed ID: 29877580
[TBL] [Abstract][Full Text] [Related]
19. Use of composite endpoints in clinical trials.
Sankoh AJ; Li H; D'Agostino RB
Stat Med; 2016 Jan; 35(2):319-20. PubMed ID: 26767752
[No Abstract] [Full Text] [Related]
20. The 2021 National Eye Institute Strategic Plan: Driving Innovation in Eye and Vision Research.
Chiang MF
Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):2. PubMed ID: 34724539
[No Abstract] [Full Text] [Related]
[Next] [New Search]
